{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:25:50Z","timestamp":1793046350687,"version":"4.5.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Limited data and guidelines exist for using nirmatrelvir\/ritonavir in solid organ transplant recipients stabilized on tacrolimus for the treatment of mild-to-moderate coronavirus disease. Concern exists regarding the impact of utilizing a 5-d course of nirmatrelvir\/ritonavir with calcineurin inhibitors because of significant drug\u2013drug interactions between ritonavir, a potent cytochrome P450 3A inhibitor, and other cytochrome P450 3A substrates, such as tacrolimus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We report the successful use of nirmatrelvir\/ritonavir in 12 outpatient lung transplant recipients with confirmed severe acute respiratory syndrome coronavirus 2 infection stabilized on tacrolimus immunosuppression. All patients stopped tacrolimus and started nirmatrelvir\/ritonavir 10 to 14 h after the last dose of tacrolimus. Tacrolimus was withheld and then reinitiated at a modified dose 48 h following the completion of nirmatrelvir\/ritonavir therapy. Tacrolimus trough levels were checked during nirmatrelvir\/ritonavir therapy and tacrolimus reinitiation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Ten (10\/12) patients were able to resume their original tacrolimus dose within 4 d of completing nirmatrelvir\/ritonavir therapy and maintain therapeutic levels of tacrolimus. No patients experienced tacrolimus toxicity or acute rejection during the 30-d postcompletion of nirmatrelvir\/ritonavir therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>In this cohort of lung transplant recipients on tacrolimus, we demonstrated that nirmatrelvir\/ritonavir can be safely used with close monitoring of tacrolimus levels and appropriate dose adjustments of tacrolimus. Further confirmatory studies are needed to determine the appropriate use of therapeutic drug monitoring and tacrolimus dose following completion of nirmatrelvir\/ritonavir in the solid organ transplant population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004394","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T21:00:08Z","timestamp":1671224408000},"page":"1200-1205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Nirmatrelvir\/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series"],"prefix":"10.1097","volume":"107","author":[{"given":"Katherine W.","family":"Dewey","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lazo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Seijo","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ripal","family":"Jariwala","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Quan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethanne","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Paul Singer","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Breen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hays","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Florez","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California, San Francisco, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"R3-20250604","first-page":"227","article-title":"Hepatorenal syndrome: pathophysiology and evidence-based management update.","volume":"59","author":"Hasan","year":"2021","journal-title":"Rom J Intern Med"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1345\/aph.1D076","article-title":"Tacrolimus and lopinavir\/ritonavir interaction in liver transplantation.","volume":"37","author":"Schonder","year":"2003","journal-title":"Ann Pharmacother"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003088-200746110-00002","article-title":"Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.","volume":"46","author":"Teicher","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"ofac238","DOI":"10.1093\/ofid\/ofac238","article-title":"Supratherapeutic tacrolimus concentrations with nirmatrelvir\/ritonavir in solid organ transplant recipients requiring hospitalization: a case series using rifampin for reversal.","volume":"9","author":"Rose","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/ajt.16955","article-title":"Nirmatrelvir\/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants.","volume":"22","author":"Lange","year":"2022","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","article-title":"Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect.","volume":"75","author":"Stader","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.ajkd.2022.01.001","article-title":"Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection.","volume":"79","author":"Fishbane","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/ajt.16997","article-title":"Effect of nirmatrelvir\/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients.","volume":"22","author":"Wang","year":"2022","journal-title":"Am J Transplant"},{"key":"R13-20250604","first-page":"1","article-title":"Early clinical experience with nirmatrelvir\/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.","volume":"00","author":"Salerno","year":"2022","journal-title":"Am J Transplant"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40262-022-01158-7","article-title":"Yes we can (use nirmatrelvir\/ritonavir even in high immunological risk patients treated with immunosuppressive drugs)!","volume":"61","author":"Lemaitre","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report.","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:11:33Z","timestamp":1749060693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004394","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}